ZC3H15 Promotes Glioblastoma Progression Through Regulating EGFR Stability

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2022 Jan 14

PMID 35027542

Authors

Jianbing Hou

Minghao Xu

Hongyu Gu

Dakun Pei

Yudong Liu

Pan Huang

Hongbo Chang

Hongjuan Cui

Affiliations

Soon will be listed here.

Abstract

Zinc finger CCCH-type containing 15 (ZC3H15), a highly conserved protein involved in several cellular processes, which was responsible for tumorigenesis and may be a promising marker in myeloid leukemia (AML) and hepatocellular carcinoma (HCC). However, little is known about the biological significance and molecular mechanisms of ZC3H15 in GBM. In this study, we revealed that ZC3H15 was overexpressed in GBM and high ZC3H15 expression was associated with poor survival of patients with GBM. We found that ZC3H15 promoted the proliferation, migration, invasion, and tumorigenesis of GBM cells by activating the EGFR signaling pathway. We also revealed that ZC3H15 reduced EGFR ubiquitination, which was responsible for EGFR protein stabilization. In addition, we demonstrated that ZC3H15 inhibited the transcription of CBL, which was an E3 ubiquitin ligase for EGFR proteasomal degradation. And silencing of CBL could partly abrogate the inhibitory effects on cell proliferation, migration, and invasion of GBM cells induced by ZC3H15 knockdown. Thus, our research revealed the important roles of ZC3H15 in GBM development and provided a brand-new insight for improving the treatment of GBMs.

Citing Articles

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFR Mutation in Non-Small Cell Lung Cancer.

Wang M, Xia Z, Nie W, Wang C, Nie H, Zhang S Drug Des Devel Ther. 2025; 19:1403-1420.

PMID: 40034406 PMC: 11874779. DOI: 10.2147/DDDT.S490303.

Comparative RNA-Seq analysis of differentially expressed genes in the sertoli cells of yak and cattle-yak.

Chen X, Wang M, Zhang P, Jing K, Yue B, Wu Z BMC Vet Res. 2025; 21(1):86.

PMID: 39987073 PMC: 11846318. DOI: 10.1186/s12917-025-04540-2.

ZC3H15 suppression ameliorates bone cancer pain through inhibiting neuronal oxidative stress and microglial inflammation.

Huang L, Yan T, Wang B, Li H, Zhou N Neoplasia. 2025; 61:101123.

PMID: 39908779 PMC: 11847137. DOI: 10.1016/j.neo.2025.101123.

Baicalein inhibits cell proliferation and induces apoptosis in brain glioma cells by downregulating the LGR4-EGFR pathway.

Zhang X, Shao X, Bao Q, He L, Qi X Cancer Gene Ther. 2024; 31(12):1856-1867.

PMID: 39468312 PMC: 11645258. DOI: 10.1038/s41417-024-00825-0.

TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21.

Zhang G, Yang R, Wang B, Yan Q, Zhao P, Zhang J Cell Death Dis. 2024; 15(8):622.

PMID: 39187490 PMC: 11347623. DOI: 10.1038/s41419-024-07012-x.

References

Vasilev A, Sofi R, Rahman R, Smith S, Teschemacher A, Kasparov S . Using Light for Therapy of Glioblastoma Multiforme (GBM). Brain Sci. 2020; 10(2). PMC: 7071600. DOI: 10.3390/brainsci10020075. View

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello M . Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2005; 366(1):2-16. DOI: 10.1016/j.gene.2005.10.018. View

Gregory R, LORD K, Panek L, Gaines P, Dillon S, Wojchowski D . Subtraction cloning and initial characterization of novel epo-immediate response genes. Cytokine. 2000; 12(7):845-57. DOI: 10.1006/cyto.2000.0686. View

Deng M, Liu B, Song H, Yu R, Zou D, Chen Y . β-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway. Phytomedicine. 2020; 69:153184. DOI: 10.1016/j.phymed.2020.153184. View

Eskilsson E, Rosland G, Solecki G, Wang Q, Harter P, Graziani G . EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2017; 20(6):743-752. PMC: 5961011. DOI: 10.1093/neuonc/nox191. View

Wout P, Sattlegger E, Sullivan S, Maddock J . Saccharomyces cerevisiae Rbg1 protein and its binding partner Gir2 interact on Polyribosomes with Gcn1. Eukaryot Cell. 2009; 8(7):1061-71. PMC: 2708457. DOI: 10.1128/EC.00356-08. View

Wang P, Zhao L, Gong S, Xiong S, Wang J, Zou D . HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia. Cell Death Dis. 2021; 12(4):312. PMC: 7990922. DOI: 10.1038/s41419-021-03598-8. View

Miyamoto Y, Suyama K, Baba H . Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci. 2017; 18(4). PMC: 5412337. DOI: 10.3390/ijms18040752. View

An Z, Aksoy O, Zheng T, Fan Q, Weiss W . Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018; 37(12):1561-1575. PMC: 5860944. DOI: 10.1038/s41388-017-0045-7. View

10.

Capalbo G, Mueller-Kuller T, Koschmieder S, Klein H, Ottmann O, Hoelzer D . Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML. Int J Oncol. 2013; 43(1):246-54. DOI: 10.3892/ijo.2013.1924. View

11.

Bareschino M, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F . Erlotinib in cancer treatment. Ann Oncol. 2007; 18 Suppl 6:vi35-41. DOI: 10.1093/annonc/mdm222. View

12.

Zhu Q, Dong H, Bukhari A, Zhao A, Li M, Sun Y . HUWE1 promotes EGFR ubiquitination and degradation to protect against renal tubulointerstitial fibrosis. FASEB J. 2020; 34(3):4591-4601. DOI: 10.1096/fj.201902751R. View

13.

Venuprasad K . Cbl-b and itch: key regulators of peripheral T-cell tolerance. Cancer Res. 2010; 70(8):3009-12. PMC: 2856114. DOI: 10.1158/0008-5472.CAN-09-4076. View

14.

Dong Q, Ma Y, Zhang Y, Qu X, Li Z, Qi Y . Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Oncotarget. 2017; 8(34):57163-57173. PMC: 5593633. DOI: 10.18632/oncotarget.18714. View

15.

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C . Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer. 2017; 140(12):2805-2819. DOI: 10.1002/ijc.30691. View

16.

Jiang B, Wan Z, Huang J, Li L, Liu H, Fu S . Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection. Oncotarget. 2016; 7(24):37238-37249. PMC: 5095072. DOI: 10.18632/oncotarget.9361. View

17.

Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello M . Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opin Pharmacother. 2018; 19(18):2055-2062. DOI: 10.1080/14656566.2018.1540591. View

18.

Duan H, Lei Z, Xu F, Pan T, Lu D, Ding P . PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer. Front Oncol. 2019; 9:790. PMC: 6716169. DOI: 10.3389/fonc.2019.00790. View

19.

Li K, Zhu X, Liu H, Zhang S, Li X, Xiao N . NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death Dis. 2020; 11(5):335. PMC: 7206140. DOI: 10.1038/s41419-020-2549-2. View

20.

Roskoski Jr R . Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2018; 139:395-411. DOI: 10.1016/j.phrs.2018.11.014. View